SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Seattle Genetics, Inc. and Certain Officers and Directors

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP announces that it has commenced an investigation of Seattle Genetics, Inc. (“Seattle Genetics” or the “Company”) (NASDAQ: SGEN) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

On December 27, 2016, Seattle Genetics announced that the U.S. Food and Drug Administration, in order to evaluate the potential risk of hepatotoxicity, had placed a clinical hold on several early stage trials of Seattle Genetics’ experimental cancer drug, vadastuximab talirine. The Company stated that six acute myeloid leukemia patients had been identified with liver toxicity and that four had died.

On this news, Seattle Genetics stock fell over 15% to close at $52.36 on December 27, 2016. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/Seattle_Genetics_SGN

or contact Joseph E. Levi, Esq. either via email at [e-mail] or by telephone at [phone], toll-free: [phone].

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.